Correlation of genetic and serologic approaches to HIV-1 subtyping in Thailand
Article Abstract:
Enzyme-linked immunosorbent assay (EIA) and the polymerase chain reaction (PCR) appear to be almost as effective as other assays for subtyping HIV-1. Researchers evaluated three different assay techniques on blood samples from 38 HIV-infected individuals: EIA, PCR and the heteroduplex mobility assay (HMA). PCR correctly identified the viral subtype in 100% of the samples typed by HMA. EIA correctly identified the viral subtype in 95% of the samples typed by HMA. EIA and PCR are simpler and less time-consuming than HMA.
Publication Name: Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology
Subject: Health
ISSN: 1077-9450
Year: 1996
User Contributions:
Comment about this article or add new information about this topic:
Genetic, antigenic and serologic characterization of human immunodeficiency virus type 1 from Indonesia
Article Abstract:
HIV-1 subtype B appears to be the predominant strain of HIV-1 in Indonesia although subtype E may also occur. Researchers used various tests to determine the viral subtype in 19 HIV-positive people. Twelve were infected with subtype B and 7 were infected with subtype E. However, 6 of the 7 infected with subtype E had been on a peacekeeping mission in Cambodia. Their viral strain was neutralized by antibodies against the Thailand E subtype. It is possible that they contracted the infection while in Thailand.
Publication Name: Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology
Subject: Health
ISSN: 1077-9450
Year: 1997
User Contributions:
Comment about this article or add new information about this topic:
Safety and immunogenicity of HIV recombinant envelope vaccines in HIV-infected infants and children
Article Abstract:
AIDS vaccines made from the HIV gp120 or gp 160 protein appear to be safe enough to use in infants and children. Researchers vaccinated 72 HIV-infected children between one month and 18 years old with a gp120 vaccine, a gp160 vaccine, or a placebo approximately every month for about six months. Sixty-five percent of those who received the vaccine developed an immune response to it, which did not occur in the placebo group.
Publication Name: Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology
Subject: Health
ISSN: 1077-9450
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Integration of behavioral and relaxation approaches into the treatment of chronic pain and insomnia. Cognitive behavioral therapy vs. zopiclone for treatment of chronic primary insomnia in older adults: A randomized controlled trial
- Abstracts: Relation between human T-lymphotropic virus type I and neurologic diseases in Panama: 1985-1990. The phylogeny and molecular epidemiology of human T-cell lymphotropic virus type II
- Abstracts: Folate, vitamin D, and iron intakes are low among pregnant Finnish women
- Abstracts: Vascular outcome in men with asymptomatic retinal cholesterol emboli: a cohort study. Recombinant human growth hormone, insulin-like growth factor 1, and combination therapy in AIDS-associated wasting: a randomized, double-blind, placebo-controlled trial
- Abstracts: Health status of well vs ill adolescents. The Pediatric Primary-Specialty Care Interface. Changes in the daily practice of primary care for children